Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)

May 30, 2024 Press Releases

PDF Version AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients to support its use as an immunotherapy in patients...

Clinical Trial Design of AT-02 Phase 2 Open-Label Extension Study in Systemic Amyloidosis

May 29, 2024 Posters & Publications

Click Here to View...

Uptake of Iodine (124I) Evuzamitide in Patients with AL and ATTR Amyloidosis and Correlation with Echocardiographic Parameters

May 28, 2024 Posters & Publications

Click Here to View...

Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer

May 28, 2024 Posters & Publications

Click Here to View...

Relationship Between Myocardial Amyloid Load Measured by 124I-evuzamitide and Prognostic Staging Systems in Transthyretin Amyloid Cardiomyopathy

May 28, 2024 Posters & Publications

Click Here to View...